Gosuranemab Biosimilar - Research Grade

Human

MAPT

>1mg/ml

IgG4 - kappa

CHO Cells

Tilavonemab Biosimilar - Research Grade (ICH5125), Zagotenemab Biosimilar - Research Grade (ICH5126), Bepranemab Biosimilar - Research Grade (ICH5391), Posdinemab Biosimilar - Research Grade (ICH5782), Semorinemab Biosimilar - Research Grade (ICH5850)

https://www.imgt.org/mAb-DB/

ICH3002

P10636

Blue ice

ICH5582 is a research-grade, unconjugated recombinant analog of gosuranemab, a humanized anti-tau antibody (human IgG4/kappa) built around the microtubule-associated protein tau (MAPT) target, specifically the extracellular N-terminal region of tau. It is supplied as a non-therapeutic reagent for research use only (RUO) and is not the clinical drug; it is not intended for human or veterinary use. The molecule reproduces the target-binding specificity of the originator, making it useful as a defined, lot-consistent tool for tau-directed experiments: positive and reference controls in binding and neutralisation assays, benchmarking of in-house anti-tau antibodies, epitope and pathway studies, and as a standard in preclinical in-vitro and cell-based tauopathy models. Available as an IgG4 isotype-matched reagent, it supports comparisons where Fc effector engagement should be minimal. It is offered at low endotoxin (research grade <1 EU/mg; ultra-low <0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, screening cascades, and scale-up work without lot-to-lot variability confounding results. MAPT (P10636) encodes tau, a microtubule-associated protein highly enriched in neuronal axons. Through its C-terminal microtubule-binding repeats, tau promotes tubulin polymerisation and stabilises microtubules, regulating microtubule dynamics, axonal transport, and neuronal polarity, while its N-terminal projection domain interacts with the plasma membrane and other partners. Alternative splicing generates six CNS isoforms (3R and 4R). Tau activity is tightly controlled by phosphorylation; pathological hyperphosphorylation reduces microtubule affinity and promotes detachment and self-aggregation into paired helical filaments and neurofibrillary tangles. These aggregates, together with cell-to-cell spread of misfolded and extracellular tau species, define the tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The N-terminal region targeted by gosuranemab corresponds to an extracellular tau species implicated in trans-neuronal propagation of tau pathology.

Neurofibrillary tangle protein, Paired helical filament-tau, PHF-tau, Microtubule-associated protein tau, MAPTL, MTBT1, TAU

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks